
Sign up to save your podcasts
Or
Vaso-occlusive pain episodes are the most common reason children and adolescents with sickle cell disease present to the Emergency Department. Prompt, protocol-driven management is essential starting with early administration of IV opioids, reassessment at 15–30 minute intervals, and judicious hydration. Understanding the patient’s typical pain pattern, opioid history, and psychosocial context can guide more effective care. This episode walks through the pathophysiology, clinical presentation, pharmacologic strategy, discharge criteria, and complications to watch for helping you provide evidence-based, compassionate care that improves outcomes.
Note: This transcript was partially completed with the use of the Descript AI and the Chat GPT 4o AI
Welcome to PEM Currents: The Pediatric Emergency Medicine Podcast. I’m your host, Brad Sobolewski. In this episode, we’re digging into a common but complex emergency department challenge: pain management for vaso-occlusive crises in children and adolescents with sickle cell disease.
These episodes are painful—literally and figuratively. But with thoughtful, evidence-based care, we can make a big difference for our patients.
Overview and Epidemiology
Vaso-occlusive crises, or VOCs, are the most frequent cause of emergency visits and hospitalizations for individuals with sickle cell disease (SCD). They are responsible for more than 70 percent of ED visits among children with SCD and account for substantial healthcare utilization and missed school days.
Most children with homozygous HbSS will experience their first painful episode before the age of 6. Recurrent VOCs are associated with higher risks of chronic pain, opioid use, and diminished quality of life.
Why Do VOCs Happen?
Sickle cell disease is caused by a point mutation in the beta-globin gene, leading to hemoglobin S. Under stress—such as infection, dehydration, or even cold exposure—red blood cells polymerize, sickle, and become rigid. These sickled cells obstruct capillaries and small vessels, leading to local tissue ischemia, inflammation, and pain.
It’s not just about the blockage—the inflammatory cascade, endothelial damage, and cytokine release all contribute to the pain experience.
What Does the Pain Feel Like?
Ask kids and teens with sickle cell disease, and they’ll describe their pain as deep, throbbing, stabbing, or aching. It often feels bone-deep and can be relentless and exhausting. Many say it’s unlike any other pain—they may compare it to being “hit with a bat,” “bone being crushed,” or “something stuck inside my limbs trying to get out.”
Common sites include:
Clinical Presentation
History
Physical Exam
Vitals
Pain scales
Management: Treat Early, Treat Effectively
Pain Medications
Adjunctive Therapies
Labs and Imaging
Oxygen
Transfusion
Disposition: Discharge vs. Admission
Discharge if:
Admit if:
Complications to Watch For
Prevention
Hydroxyurea is the cornerstone of prevention. It increases fetal hemoglobin and reduces the frequency and severity of pain crises. It can be started as early as 9 months of age in children with HbSS or Sβ⁰-thalassemia.
Other preventive strategies include:
Take-Home Points
4.6
8181 ratings
Vaso-occlusive pain episodes are the most common reason children and adolescents with sickle cell disease present to the Emergency Department. Prompt, protocol-driven management is essential starting with early administration of IV opioids, reassessment at 15–30 minute intervals, and judicious hydration. Understanding the patient’s typical pain pattern, opioid history, and psychosocial context can guide more effective care. This episode walks through the pathophysiology, clinical presentation, pharmacologic strategy, discharge criteria, and complications to watch for helping you provide evidence-based, compassionate care that improves outcomes.
Note: This transcript was partially completed with the use of the Descript AI and the Chat GPT 4o AI
Welcome to PEM Currents: The Pediatric Emergency Medicine Podcast. I’m your host, Brad Sobolewski. In this episode, we’re digging into a common but complex emergency department challenge: pain management for vaso-occlusive crises in children and adolescents with sickle cell disease.
These episodes are painful—literally and figuratively. But with thoughtful, evidence-based care, we can make a big difference for our patients.
Overview and Epidemiology
Vaso-occlusive crises, or VOCs, are the most frequent cause of emergency visits and hospitalizations for individuals with sickle cell disease (SCD). They are responsible for more than 70 percent of ED visits among children with SCD and account for substantial healthcare utilization and missed school days.
Most children with homozygous HbSS will experience their first painful episode before the age of 6. Recurrent VOCs are associated with higher risks of chronic pain, opioid use, and diminished quality of life.
Why Do VOCs Happen?
Sickle cell disease is caused by a point mutation in the beta-globin gene, leading to hemoglobin S. Under stress—such as infection, dehydration, or even cold exposure—red blood cells polymerize, sickle, and become rigid. These sickled cells obstruct capillaries and small vessels, leading to local tissue ischemia, inflammation, and pain.
It’s not just about the blockage—the inflammatory cascade, endothelial damage, and cytokine release all contribute to the pain experience.
What Does the Pain Feel Like?
Ask kids and teens with sickle cell disease, and they’ll describe their pain as deep, throbbing, stabbing, or aching. It often feels bone-deep and can be relentless and exhausting. Many say it’s unlike any other pain—they may compare it to being “hit with a bat,” “bone being crushed,” or “something stuck inside my limbs trying to get out.”
Common sites include:
Clinical Presentation
History
Physical Exam
Vitals
Pain scales
Management: Treat Early, Treat Effectively
Pain Medications
Adjunctive Therapies
Labs and Imaging
Oxygen
Transfusion
Disposition: Discharge vs. Admission
Discharge if:
Admit if:
Complications to Watch For
Prevention
Hydroxyurea is the cornerstone of prevention. It increases fetal hemoglobin and reduces the frequency and severity of pain crises. It can be started as early as 9 months of age in children with HbSS or Sβ⁰-thalassemia.
Other preventive strategies include:
Take-Home Points
1,864 Listeners
127 Listeners
536 Listeners
251 Listeners
506 Listeners
305 Listeners
98 Listeners
3,337 Listeners
257 Listeners
1,117 Listeners
516 Listeners
257 Listeners
226 Listeners
314 Listeners
237 Listeners